Laddar...
Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
PURPOSE: The OVA-YOND study is the first prospective, non-interventional trial designed to evaluate trabectedin (1.1 mg/m(2)) plus PLD (30 mg/m(2)) in patients with platinum-sensitive recurrent ovarian cancer (ROC), given according to the marketing authorization in real-life clinical practice across...
Sparad:
| I publikationen: | J Cancer Res Clin Oncol |
|---|---|
| Huvudupphovsmän: | , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Springer Berlin Heidelberg
2018
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5948298/ https://ncbi.nlm.nih.gov/pubmed/29623421 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-018-2637-1 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|